unknown
Stage
About
Vytala develops a plant-based medical food and lipid delivery technology (Lym-X-Sorb) designed to improve absorption of fats, calories, choline, and essential fatty acids for patients with fat malabsorption and gastrointestinal disorders. Clinical studies cited on the company website report improved nutrient absorption and growth metrics in pediatric cystic fibrosis and pancreatic insufficiency patients, and the product is presented as eligible for CMS reimbursement.
Explore Vytala's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.